Literature DB >> 8811440

Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection.

M Y Zeng1, Z L Lu, S C Yang, M Zhang, J Liao, S L Liu, X H Teng.   

Abstract

A reversed-phase high-performance liquid chromatographic method for the determination of benflumetol in human plasma is described. Benflumetol in plasma samples was extracted with a glacial acetic acid-ethyl acetate (1:100, v/v) mixture at pH 4.0. Chromatography was performed on a Spherisorb C18 column using a methanol-water-glacial acetic acid-diethyl amine (93:6:1:0.03, v/v) mixture as the mobile phase and UV-VIS detection at 335 nm. The identity and purity of the benflumetol peak were carefully examined, and the internal standard method was applied for its quantitation. The absolute recovery of benflumetol in spiked plasma samples was 92.91% over the concentration range 5-4000 ng/ml. The recovery of internal standard "8212" at a concentration of 300 ng/ml in spiked plasma was 84.85%. The detection limit of benflumetol was 11.8 ng/ml. Plasma concentration-time profiles in healthy volunteer adults were measured after a single-dose oral administration of 500 mg of benflumetol. The assay procedures were within the quality control limits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811440     DOI: 10.1016/0378-4347(95)00542-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  9 in total

1.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

2.  Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Authors:  F Ezzet; M van Vugt; F Nosten; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

4.  Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation.

Authors:  Liusheng Huang; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  Bioanalysis       Date:  2012-01       Impact factor: 2.681

5.  Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.

Authors:  Peter Starzengruber; Gunther Wernsdorfer; Maria Parizek; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study.

Authors:  Liusheng Huang; Patricia S Lizak; Anura L Jayewardene; Florence Marzan; Ming-Na Tina Lee; Francesca T Aweeka
Journal:  Anal Chem Insights       Date:  2010-03-29

7.  A simple and precise method for quantitative analysis of lumefantrine by planar chromatography.

Authors:  Purnima Hamrapurkar; Mitesh Phale; Sandeep Pawar; Priti Patil; Mittal Gandhi
Journal:  Pharm Methods       Date:  2010-10

8.  Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product.

Authors:  Omary M S Minzi; Ignace A Marealle; Seif Shekalaghe; Omar Juma; Eliford Ngaimisi; Mwajuma Chemba; Mastidia Rutaihwa; Salim Abdulla; Philip Sasi
Journal:  Malar J       Date:  2013-05-30       Impact factor: 2.979

Review 9.  Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.

Authors: 
Journal:  BMC Med       Date:  2015-09-18       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.